BioAlliance receives ANR funding
To develop new applications of its mucoadheasive Lauriad technology
BioAlliance Pharma, a company dedicated to the supportive care and treatment of cancer patients, has received a grant from the French state Research National Agency (ANR) and a label award from Medicen Paris Region and Atlanpole, for two new applications of its mucoadhesive Lauriad technology.
The ANR funding will be allocated to the development of a Lauriad mucoadhesive tablet containing a siRNA (small interfering RNA targeting the androgen receptors) for the treatment of castration-resistant prostate cancer. This programme is managed in partnership with SeleXel, the company developing this biological molecule. This proof of concept should be extended to other similar molecules.
Medicen Paris Region and Atlanpole have also granted another label to Fluriad, a programme involving several academic centres (Paris XI and Lyon 1 Universities, Nice University Hospital) and industrial partners (Sogeval, a veterinary drug company and Gredeco, developing mucous penetration models). The consortium, led by BioAlliance, is designing vaccines administered by the mucosal route, using the innovative properties of the mucoadhesive Lauriad technology.
These new collaborations involving the Lauriad mucoadhesive delivery system are essentially based on the achievements and clinical experience from BioAlliance Pharma’s first two products (Loramyc, registered in Europe and in the US, and Sitavir, for which the registration dossier is to be filed).
‘This new mucosal route has been validated by the European and US agencies and opens new opportunities for the mucosal administration of complex biological products,’ said Dominique Costantini, chief executive BioAlliance Pharma.